Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer

Wu, Dong; Qian, Jia Ming; Deng, Rui-Xue; Jiang, Wei; Chen, Yuan Jia; Liu, Xiao Hong; Xing, Lu

doi:10.1111/j.1443-9573.2006.00249.x

Cited by 6 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with this result, and with another recent proteomic analysis of pancreatic ductal fluid by Gao, et al, we detected decreased elastase proteins (ELA2A, 3A, and 3B) in cancer 10 . However, increased levels of elastase 3b (formerly designated elastase 1) in pancreatic cancer tissue samples have been observed by several groups 30-35 . Considering the full range of proteomic analyses completed to date, the utility of elastase 3b as a biomarker for pancreatic cancer is in doubt, especially in light of its reported changes in pancreatitis as well as cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Consistent with this result, and with another recent proteomic analysis of pancreatic ductal fluid by Gao et al, we detected decreased elastase proteins (ELA2A, 3A, and 3B) in cancer . However, increased levels of elastase 3b (formerly designated elastase 1) in pancreatic cancer tissue samples have been observed by several groups. − Considering the full range of proteomic analyses completed to date, the utility of elastase 3b as a biomarker for pancreatic cancer is in doubt, especially in light of its reported changes in pancreatitis as well as cancer. Pancreatic lipase-related protein 2 (LIPR2), which is the major colipase-dependent lipase in the pancreas, has been implicated in tumor cell killing through apoptotic and necrotic death induced by high levels of unsaturated fatty acids. − Consistent with the proteomic results presented here, pancreatic lipase immunoreactivity in serum was shown to decrease in pancreatic cancer .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Discrimination between Adenocarcinoma and Normal Pancreatic Ductal Fluid by Proteomic and Glycomic Analysis

Porterfield

Zhao²,

Han

et al. 2013

J. Proteome Res.

View full text Add to dashboard Cite

Sensitive and specific biomarkers for pancreatic cancer are currently unavailable. The high mortality associated with adenocarcinoma of the pancreatic epithelium justifies the broadest possible search for new biomarkers that can facilitate early detection or monitor treatment efficacy. Protein glycosylation is altered in many cancers, leading many to propose that glycoproteomic changes may provide suitable biomarkers. In order to assess this possibility for pancreatic cancer, we have performed an in-depth LC-MS/MS analysis of the proteome and MSn-based characterization of the N-linked glycome of a small set of pancreatic ductal fluid obtained from normal, pancreatitis, intraductal papillary mucinous neoplasm (IPMN), and pancreatic adenocarcinoma patients. Our results identify a set of seven proteins that were consistently increased in cancer ductal fluid compared to normal (AMYP, PRSS1, GP2-1, CCDC132, REG1A, REG1B, and REG3A) and one protein that was consistently decreased (LIPR2). These proteins are all directly or indirectly associated with the secretory pathway in normal pancreatic cells. Validation of these changes in abundance by Western blotting revealed increased REG protein glycoform diversity in cancer. Characterization of the total N-linked glycome of normal, IPMN, and adenocarcinoma ductal fluid clustered samples into three discrete groups based on the prevalence of 6 dominant glycans. Within each group, the profiles of less prevalent glycans were able to distinguish normal from cancer on this small set of samples. Our results emphasize that individual variation in protein glycosylation must be considered when assessing the value of a glycoproteomic marker, but also indicate that glycosylation diversity across human subjects can be reduced to simpler clusters of individuals whose N-linked glycans share structural features.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Discrimination between Adenocarcinoma and Normal Pancreatic Ductal Fluid by Proteomic and Glycomic Analysis

Porterfield

Zhao²,

Han

et al. 2013

J. Proteome Res.

View full text Add to dashboard Cite

show abstract

“…2 In clinical studies, the inflammation of pancreas or pancreatic duct obstruction, for example, as caused by pancreatitis or neoplasm, would result in abnormally high pressure in the pancreas, followed by stasis of pancreatic secretion, consequently allowing PE-1 to be released into the systemic circulation. 3 Therefore, elevated PE-1 levels in the blood may indicate pancreatic disorders, with PE-1 having been investigated in the diagnosis of acute pancreatitis in previous studies. [4][5][6] Moreover, PE-1 may be useful in detecting early-stage pancreatic neoplasms or early recurrence after pancreatic cancer surgery.…”

Section: Introductionmentioning

confidence: 99%

Establishing the blood reference interval of pancreatic elastase‐1: A prospective study

Chi

Lai

Dong

et al. 2021

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim: Pancreatic elastase-1 (PE-1) has been investigated in pancreatic disorders. However, the reference interval (RI) of PE-1 in blood remains unconfirmed. We aimed to establish the blood RI of PE-1 in an adult population. Methods: In this prospective cross-sectional study, we enrolled 400 adults who had received the whole-body physical check-up program between May 1, 2019 and November 20, 2019. The serum and plasma PE-1 levels were measured by latex turbidimetric immunoassay in different storage conditions (fresh, refrigerated, and frozen). The 95% and 99% RI of PE-1 were calculated according to the Clinical & Laboratory Standards Institute guidelines. The correlations between PE-1 and other parameters were analyzed using multivariable regression models. Ultimately, 38 patients with acute pancreatitis were prospectively recruited as the validation cohort. Results: The PE-1 levels in fresh serum were highly correlated with those in refrigerated (R 2 = 0.998) or frozen (R 2 = 0.942) samples; however, plasma should not be suggested in frozen conditions (plasma vs serum: R 2 = 0.185). In the RI study population (202 male & 198 female participants), the median age was 52.6 (25-75% interquartile range: 43.1-61.0). The 95% and 99% RIs of PE-1 were 30.0-221.0 and 22.0-359.0 ng/dL, respectively. Triglycerides (β = 0.106, P = 0.033), lipase (β = 0.154, P = 0.007), and CA19-9 (β = 0.130, P = 0.008) were independent factors associated with PE-1. In the pancreatitis validation cohort, with a cut-off value of 359.0 ng/dL, the sensitivity and specificity were 100% and 99.8%, respectively. Conclusion:The RI of PE-1 established in this study can be used for further applications. Serum is the suggested form for frozen sample storage.

show abstract

Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma

Yang

Lin

Chen

et al. 2022

Journal of the Formosan Medical Association

View full text Add to dashboard Cite

Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer

Cited by 6 publications

References 10 publications

Discrimination between Adenocarcinoma and Normal Pancreatic Ductal Fluid by Proteomic and Glycomic Analysis

Discrimination between Adenocarcinoma and Normal Pancreatic Ductal Fluid by Proteomic and Glycomic Analysis

Establishing the blood reference interval of pancreatic elastase‐1: A prospective study

Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About